Treg and Oligoclonal Expansion of Terminal Effector CD8 T Cell As Key Players in Multiple Myeloma

Overview

Journal Front Immunol

Specialty Allergy & Immunology

Date 2021 Mar 12

PMID 33708212

Citations 12

Authors

Douglas E Joshua

Slavica Vuckovic

James Favaloro

Ka Hei Aleks Lau

Shihong Yang

Christian E Bryant

John Gibson

Phoebe Joy Ho

Affiliations

Soon will be listed here.

Abstract

The classical paradigm of host-tumor interaction, i.e. elimination, equilibrium, and escape (EEE), is reflected in the clinical behavior of myeloma which progresses from the premalignant condition, Monoclonal Gammopathy of Unknown Significance (MGUS). Despite the role of other immune cells, CD4 regulatory T cells (Treg) and cytotoxic CD8 T cells have emerged as the dominant effectors of host control of the myeloma clone. Progression from MGUS to myeloma is associated with alterations in Tregs and terminal effector CD8 T cells (T). These changes involve CD39 and CD69 expression, affecting the adenosine pathway and residency in the bone marrow (BM) microenvironment, together with oligoclonal expansion within CD8 T cells. In this mini-review article, in the context of earlier data, we summarize our recent understanding of Treg involvement in the adenosine pathway, the significance of oligoclonal expansion within CD8 T cells and BM-residency of CD8 T cells in MGUS and newly diagnosed multiple myeloma patients.

Citing Articles

A novel defined risk signature of ferroptosis-related lncRNAs for predicting prognosis, immune infiltration, and chemotherapy response in multiple myeloma.

Yu W, Jing Z, Tang J, Chen J Discov Oncol. 2025; 16(1):160.

PMID: 39934434 PMC: 11813854. DOI: 10.1007/s12672-025-01947-z.

Monoclonal gammopathy in systemic lupus erythematosus is associated with distinctive clinical course, malignancy and mortality rate: a single-centre retrospective cohort study.

Siwiec-Kozlik A, Kozlik-Siwiec P, Spalkowska M, Korkosz M, Kosalka-Wegiel J Lupus Sci Med. 2024; 11(2).

PMID: 39216876 PMC: 11367329. DOI: 10.1136/lupus-2024-001248.

Different evasion strategies in multiple myeloma.

Wang C, Wang W, Wang M, Deng J, Sun C, Hu Y Front Immunol. 2024; 15:1346211.

PMID: 38464531 PMC: 10920326. DOI: 10.3389/fimmu.2024.1346211.

Enhancing prognostic power in multiple myeloma using a plasma cell signature derived from single-cell RNA sequencing.

Li J, Arsang-Jang S, Cheng Y, Sun F, DSouza A, Dhakal B Blood Cancer J. 2024; 14(1):38.

PMID: 38443358 PMC: 10915134. DOI: 10.1038/s41408-024-01024-8.

Good Cop, Bad Cop: Profiling the Immune Landscape in Multiple Myeloma.

Sharma N, Choudhary B Biomolecules. 2023; 13(11).

PMID: 38002311 PMC: 10669790. DOI: 10.3390/biom13111629.

References

Zelle-Rieser C, Thangavadivel S, Biedermann R, Brunner A, Stoitzner P, Willenbacher E . T cells in multiple myeloma display features of exhaustion and senescence at the tumor site. J Hematol Oncol. 2016; 9(1):116. PMC: 5093947. DOI: 10.1186/s13045-016-0345-3. View

Sze D, Brown R, Yuen E, Gibson J, Ho J, Raitakari M . Clonal cytotoxic T cells in myeloma. Leuk Lymphoma. 2003; 44(10):1667-74. DOI: 10.1080/1042819031000097438. View

Bryant C, Suen H, Brown R, Yang S, Favaloro J, Aklilu E . Long-term survival in multiple myeloma is associated with a distinct immunological profile, which includes proliferative cytotoxic T-cell clones and a favourable Treg/Th17 balance. Blood Cancer J. 2013; 3:e148. PMC: 3789202. DOI: 10.1038/bcj.2013.34. View

Marsh-Wakefield F, Kruzins A, McGuire H, Yang S, Bryant C, Fazekas de St. Groth B . Mass Cytometry Discovers Two Discrete Subsets of CD39Treg Which Discriminate MGUS From Multiple Myeloma. Front Immunol. 2019; 10:1596. PMC: 6688400. DOI: 10.3389/fimmu.2019.01596. View

Leone P, Di Lernia G, Solimando A, Cicco S, Saltarella I, Lamanuzzi A . Bone marrow endothelial cells sustain a tumor-specific CD8 T cell subset with suppressive function in myeloma patients. Oncoimmunology. 2018; 8(1):e1486949. PMC: 6287798. DOI: 10.1080/2162402X.2018.1486949. View

Brown R, Kabani K, Favaloro J, Yang S, Ho P, Gibson J . CD86+ or HLA-G+ can be transferred via trogocytosis from myeloma cells to T cells and are associated with poor prognosis. Blood. 2012; 120(10):2055-63. DOI: 10.1182/blood-2012-03-416792. View

Lomas O, Tahri S, Ghobrial I . The microenvironment in myeloma. Curr Opin Oncol. 2020; 32(2):170-175. DOI: 10.1097/CCO.0000000000000615. View

Richmond J, Strassner J, Rashighi M, Agarwal P, Garg M, Essien K . Resident Memory and Recirculating Memory T Cells Cooperate to Maintain Disease in a Mouse Model of Vitiligo. J Invest Dermatol. 2018; 139(4):769-778. PMC: 6431571. DOI: 10.1016/j.jid.2018.10.032. View

Noonan K, Marchionni L, Anderson J, Pardoll D, Roodman G, Borrello I . A novel role of IL-17-producing lymphocytes in mediating lytic bone disease in multiple myeloma. Blood. 2010; 116(18):3554-63. PMC: 4017298. DOI: 10.1182/blood-2010-05-283895. View

10.

Miyara M, Yoshioka Y, Kitoh A, Shima T, Wing K, Niwa A . Functional delineation and differentiation dynamics of human CD4+ T cells expressing the FoxP3 transcription factor. Immunity. 2009; 30(6):899-911. DOI: 10.1016/j.immuni.2009.03.019. View

11.

Noonan K, Huff C, Davis J, Lemas M, Fiorino S, Bitzan J . Adoptive transfer of activated marrow-infiltrating lymphocytes induces measurable antitumor immunity in the bone marrow in multiple myeloma. Sci Transl Med. 2015; 7(288):288ra78. PMC: 4634889. DOI: 10.1126/scitranslmed.aaa7014. View

12.

Raja K, Hajek R . Contribution of regulatory T cells to immunosuppression and disease progression in multiple myeloma patients. Oncoimmunology. 2013; 2(9):e25619. PMC: 3850022. DOI: 10.4161/onci.25619. View

13.

Chillemi A, Quarona V, Antonioli L, Ferrari D, Horenstein A, Malavasi F . Roles and Modalities of Ectonucleotidases in Remodeling the Multiple Myeloma Niche. Front Immunol. 2017; 8:305. PMC: 5357780. DOI: 10.3389/fimmu.2017.00305. View

14.

Borsellino G, Kleinewietfeld M, Di Mitri D, Sternjak A, Diamantini A, Giometto R . Expression of ectonucleotidase CD39 by Foxp3+ Treg cells: hydrolysis of extracellular ATP and immune suppression. Blood. 2007; 110(4):1225-32. DOI: 10.1182/blood-2006-12-064527. View

15.

Kumar B, Ma W, Miron M, Granot T, Guyer R, Carpenter D . Human Tissue-Resident Memory T Cells Are Defined by Core Transcriptional and Functional Signatures in Lymphoid and Mucosal Sites. Cell Rep. 2017; 20(12):2921-2934. PMC: 5646692. DOI: 10.1016/j.celrep.2017.08.078. View

16.

Favaloro J, Brown R, Aklilu E, Yang S, Suen H, Hart D . Myeloma skews regulatory T and pro-inflammatory T helper 17 cell balance in favor of a suppressive state. Leuk Lymphoma. 2013; 55(5):1090-8. DOI: 10.3109/10428194.2013.825905. View

17.

Horenstein A, Quarona V, Toscani D, Costa F, Chillemi A, Pistoia V . Adenosine Generated in the Bone Marrow Niche Through a CD38-Mediated Pathway Correlates with Progression of Human Myeloma. Mol Med. 2016; 22:694-704. PMC: 5135080. DOI: 10.2119/molmed.2016.00198. View

18.

Bastid J, Regairaz A, Bonnefoy N, Dejou C, Giustiniani J, Laheurte C . Inhibition of CD39 enzymatic function at the surface of tumor cells alleviates their immunosuppressive activity. Cancer Immunol Res. 2014; 3(3):254-65. DOI: 10.1158/2326-6066.CIR-14-0018. View

19.

Dong S, Ghobrial I . Autologous graft versus myeloma: it's not a myth. J Clin Invest. 2018; 129(1):48-50. PMC: 6307964. DOI: 10.1172/JCI125431. View

20.

Corgnac S, Boutet M, Kfoury M, Naltet C, Mami-Chouaib F . The Emerging Role of CD8 Tissue Resident Memory T (T) Cells in Antitumor Immunity: A Unique Functional Contribution of the CD103 Integrin. Front Immunol. 2018; 9:1904. PMC: 6104123. DOI: 10.3389/fimmu.2018.01904. View